Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells

References

• Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189(9):1363–9. doi:10.1084/jem.189.9.1363.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–268. doi:10.1038/nri3175.
   PubMed Web of Science ®Google Scholar
• Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G. et al. IL-4-Induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003;170(1):270–278. doi:10.4049/jimmunol.170.1.270.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781–790. doi:10.1084/jem.20131916.
   PubMed Web of Science ®Google Scholar
• Yu Y, Cui J. Present and future of cancer immunotherapy: a tumor microenvironmental perspective (review). Oncol Lett. 2018. doi:10.3892/ol.2018.9219.
   Web of Science ®Google Scholar
• Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses. Front Immunol. 2020;11:940. doi:10.3389/fimmu.2020.00940.
   PubMed Web of Science ®Google Scholar
• Andersen MH. Anti-regulatory T cells. Semin Immunopathol. 2017;39(3):317–326. doi:10.1007/s00281-016-0593-x.
   PubMed Web of Science ®Google Scholar
• Andersen MH. Tumor microenvironment antigens. Semin Immunopathol. 2022;45(2):253–264. doi:10.1007/s00281-022-00966-0.
   PubMed Web of Science ®Google Scholar
• Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, Met Ö, Donia M, Svane IM, Andersen MH. et al. Frequent adaptive immune responses against arginase-1. Oncoimmunology. 2017;7(3):e1404215. doi:10.1080/2162402X.2017.1404215.
   PubMed Web of Science ®Google Scholar
• Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TNM, Svane IM, Becker JC, Straten PT, Andersen MH. et al. The immune system strikes back: cellular immune responses against Indoleamine 2,3-dioxygenase. PloS One. 2009;4(9):e6910. doi:10.1371/journal.pone.0006910.
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 + T cells. Oncoimmunology. 2013;2(4):e23991. doi:10.4161/onci.23991.
   PubMed Web of Science ®Google Scholar
• Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE. et al. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021;27(12):2212–2223. doi:10.1038/s41591-021-01544-x.
   PubMed Web of Science ®Google Scholar
• Lorentzen CL, Kjeldsen JW, Ehrnrooth E, Andersen MH, Marie Svane I. Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab. J Immunother Cancer. 2023;11(5):e006755. doi:10.1136/jitc-2023-006755.
   PubMed Web of Science ®Google Scholar
• Mondanelli G, Ugel S, Grohmann U, Bronte V. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. Curr Opin Pharmacol. 2017;35:30–39. doi:10.1016/j.coph.2017.05.002.
   PubMed Web of Science ®Google Scholar
• Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003;24(6):301–305. doi:10.1016/S1471-4906(03)00132-7.
   Web of Science ®Google Scholar
• Canè S, Barouni RM, Fabbi M, Cuozzo J, Fracasso G, Adamo A, Ugel S, Trovato R, De Sanctis F, Giacca M. et al. Neutralization of NET-associated human ARG1 enhances cancer immunotherapy. Sci Transl Med. 2023;15(687). doi:10.1126/scitranslmed.abq6221.
   PubMed Web of Science ®Google Scholar
• Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, Wolinska E, Gaj P, Grazul M, Pilch Z. et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10(1):3000. doi:10.1038/s41467-019-10979-3.
   PubMed Web of Science ®Google Scholar
• de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunology. 2012;1(8):1305–1312. doi:10.4161/onci.21678.
   PubMed Web of Science ®Google Scholar
• Ma Z, Lian J, Yang M, Wuyang J, Zhao C, Chen W, Liu C, Zhao Q, Lou C, Han J. et al. Overexpression of arginase-1 is an indicator of poor prognosis in patients with colorectal cancer. Pathol Res Pract. 2019;215(6):152383. doi:10.1016/j.prp.2019.03.012.
   PubMed Web of Science ®Google Scholar
• Andersen MH. The balance players of the adaptive immune system. Cancer Res. 2018;78(6):1379–1382. doi:10.1158/0008-5472.CAN-17-3607.
   PubMed Web of Science ®Google Scholar
• Martinenaite E, Ahmad SM, Svane IM, Andersen MH. Peripheral memory T cells specific for arginase-1. Cell Mol Immunol. 2019;168(8):718–719. doi:10.1038/s41423-019-0231-3.
   Google Scholar
• Martinenaite E, Ahmad SM, Bendtsen SK, Jørgensen MA, Weis-Banke SE, Svane IM, Andersen MH. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. Cancer Immunol Immunother. 2019;68(11):1901–1907. doi:10.1007/s00262-019-02425-6.
   PubMed Web of Science ®Google Scholar
• Lorentzen CL, Martinenaite E, Kjeldsen JW, Holmstroem RB, Mørk SK, Pedersen AW, Ehrnrooth E, Andersen MH, Svane IM. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – a phase I trial. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.1023023.
   PubMed Web of Science ®Google Scholar
• Grauslund JH, Holmström MO, Martinenaite E, Lisle TL, Glöckner HJ, El Fassi D, Klausen U, Mortensen REJ, Jørgensen N, Kjær L. et al. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: a first-in-man clinical trial. Front Immunol. 2023;14. doi:10.3389/fimmu.2023.1117466.
   PubMed Web of Science ®Google Scholar
• Andersen MH, Bonfill JE, Neisig A, Arsequell G, Søndergaard I, Neefjes J, Zeuthen J, Elliott T, Haurum JS. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol. 1999;163(7):3812–3818. doi:10.4049/jimmunol.163.7.3812.
   PubMed Web of Science ®Google Scholar
• Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF. High‐Throughput Real‐Time Quantitative Reverse Transcription PCR. Curr. Protoc. Mol. Biol. 2006;73(1):15.8.1–15.8.28. doi:10.1002/0471142727.mb1508s73.
   Google Scholar
• Moodie Z, Price L, Janetzki S, Britten CM. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol. 2012;792:185–196.
   PubMedGoogle Scholar
• Thor Straten P, Guldberg P, Grønbæk K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol. 1999;163(1):443–447. doi:10.4049/jimmunol.163.1.443.
   PubMed Web of Science ®Google Scholar
• Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol. 1998;160(11):5347–5354. doi:10.4049/jimmunol.160.11.5347.
   PubMed Web of Science ®Google Scholar
• Munder M, Eichmann K, Morán JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol. 1999;163(7):3771–3777. doi:10.4049/jimmunol.163.7.3771.
   PubMed Web of Science ®Google Scholar
• Jørgensen MA. Ugel S, Linder Hübbe M, Carretta M, Perez-Penco M, Weis-Banke, SE, Martinenaite E, Kopp K, Chapellier M, Adamo A, De Sanctis F. et al. Arginase 1–based immune modulatory vaccines induce anticancer immunity and synergize with anti–PD-1 checkpoint blockade. Cancer Immunol Res. 2021. doi:10.1158/2326-6066.CIR-21-0280.
   Web of Science ®Google Scholar
• Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, Lapurga G, Jiang K, Butchar JP, Tridandapani S. et al. Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. J Immunother Cancer. 2019;7(1):140. doi:10.1186/s40425-019-0622-0.
   PubMedGoogle Scholar
• Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol. 1995;155(4):2077–2084. doi:10.4049/jimmunol.155.4.2077.
   PubMed Web of Science ®Google Scholar
• Fernando MR, Reyes JL, Iannuzzi J, Leung G, McKay DM, Wallace J. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One. 2014;9(4):e94188. doi:10.1371/journal.pone.0094188.
   PubMed Web of Science ®Google Scholar
• Dey S, Sutanto-Ward E, Kopp KL, DuHadaway J, Mondal A, Ghaban D, Lecoq I, Zocca M-B, Merlo LMF, Mandik-Nayak L. et al. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. J Immunother Cancer. 2020;8(2):e000605. doi:10.1136/jitc-2020-000605.
   PubMed Web of Science ®Google Scholar